You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Sorafenib tosylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sorafenib tosylate and what is the scope of freedom to operate?

Sorafenib tosylate is the generic ingredient in two branded drugs marketed by Bayer Hlthcare, Dr Reddys, Mylan, Teva Pharms Usa Inc, Torrent, and Yabao Pharm, and is included in six NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sorafenib tosylate has eighty-nine patent family members in thirty-nine countries.

There are twelve drug master file entries for sorafenib tosylate. Eight suppliers are listed for this compound.

Recent Clinical Trials for sorafenib tosylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
First Affiliated Hospital of Shantou University Medical CollegePhase 2/Phase 3
The First Affiliated Hospital of Guangzhou Medical UniversityPhase 2/Phase 3
Maternal and Child Health Hospital of FoshanPhase 2/Phase 3

See all sorafenib tosylate clinical trials

Pharmacology for sorafenib tosylate
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Paragraph IV (Patent) Challenges for SORAFENIB TOSYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NEXAVAR Tablets sorafenib tosylate 200 mg 021923 1 2014-02-28

US Patents and Regulatory Information for sorafenib tosylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Teva Pharms Usa Inc SORAFENIB TOSYLATE sorafenib tosylate TABLET;ORAL 209567-001 Nov 12, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Torrent SORAFENIB TOSYLATE sorafenib tosylate TABLET;ORAL 217095-001 Apr 12, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys SORAFENIB TOSYLATE sorafenib tosylate TABLET;ORAL 216073-001 Jun 7, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Yabao Pharm SORAFENIB TOSYLATE sorafenib tosylate TABLET;ORAL 209050-001 Nov 9, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan SORAFENIB TOSYLATE sorafenib tosylate TABLET;ORAL 207012-001 Sep 10, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for sorafenib tosylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for sorafenib tosylate

Country Patent Number Title Estimated Expiration
Guatemala 200600096 COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DEL CANCER ⤷  Sign Up
Norway 344272 ⤷  Sign Up
China 101132779 Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer ⤷  Sign Up
European Patent Office 1797038 FORME THERMODYNAMIQUEMENT STABLE DE TOSYLATE DE BAY 43-9006 (THERMODYNAMICALLY STABLE FORM OF BAY 43-9006 TOSYLATE) ⤷  Sign Up
Norway 343834 ⤷  Sign Up
Peru 20061345 COMPOSICION FARMACEUTICA QUE COMPRENDE SORAFENIB ⤷  Sign Up
South Africa 200707638 Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for sorafenib tosylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1140840 PA2006008 Lithuania ⤷  Sign Up PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840 122006000059 Germany ⤷  Sign Up PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840 SZ 35/2006 Austria ⤷  Sign Up PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON
1140840 SPC/GB07/004 United Kingdom ⤷  Sign Up PRODUCT NAME: SORAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/06/342/001 20060721
1140840 CA 2007 00002 Denmark ⤷  Sign Up PRODUCT NAME: SORAFENIB TOSYLAT
1140840 35/2006 Austria ⤷  Sign Up PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840 PA2006008,C1140840 Lithuania ⤷  Sign Up PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.